BMC Developmental Biology

official impact factor 2.78

Open Access Research article

Reduced-folate carrier (RFC) is expressed in placenta and yolk sac, as well as in cells of the developing forebrain, hindbrain, neural tube, craniofacial region, eye, limb buds and heart

Dennis M Maddox1, Anna Manlapat1, Penny Roon1, Puttur Prasad2, Vadivel Ganapathy3 and Sylvia B Smith1,4*

Author Affiliations

1 Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta, USA

2 Department of Obstetrics and Gynecology, Medical College of Georgia, Augusta, USA

3 Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, USA

4 Department of Ophthalmology, Medical College of Georgia, Augusta, USA

For all author emails, please log on.

BMC Developmental Biology 2003, 3:6 doi:10.1186/1471-213X-3-6

Published: 29 July 2003

Abstract

Background

Folate is essential for cellular proliferation and tissue regeneration. As mammalian cells cannot synthesize folates de novo, tightly regulated cellular uptake processes have evolved to sustain sufficient levels of intracellular tetrahydrofolate cofactors to support biosynthesis of purines, pyrimidines, and some amino acids (serine, methionine). Though reduced-folate carrier (RFC) is one of the major proteins mediating folate transport, knowledge of the developmental expression of RFC is lacking. We utilized in situ hybridization and immunolocalization to determine the developmental distribution of RFC message and protein, respectively.

Results

In the mouse, RFC transcripts and protein are expressed in the E10.0 placenta and yolk sac. In the E9.0 to E11.5 mouse embryo RFC is widely detectable, with intense signal localized to cell populations in the neural tube, craniofacial region, limb buds and heart. During early development, RFC is expressed throughout the eye, but by E12.5, RFC protein becomes localized to the retinal pigment epithelium (RPE).

Conclusions

Clinical studies show a statistical decrease in the number of neural tube defects, craniofacial abnormalities, cardiovascular defects and limb abnormalities detected in offspring of female patients given supplementary folate during pregnancy. The mechanism, however, by which folate supplementation ameliorates the occurrence of developmental defects is unclear. The present work demonstrates that RFC is present in placenta and yolk sac and provides the first evidence that it is expressed in the neural tube, craniofacial region, limb buds and heart during organogenesis. These findings suggest that rapidly dividing cells in the developing neural tube, craniofacial region, limb buds and heart may be particularly susceptible to folate deficiency.